Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: Anxiety, risk perceptions, and quality of life

Gynecologic Oncology

Volumn 89, Issue 3, 2003, Pages 440-446

  Hensley, Martee L ^a,b   Robson, Mark E ^a   Kauff, Noah D ^a   Korytowsky, Beata ^a   Castiel, Mercedes ^a   Ostroff, Jamie ^a   Hurley, Karen ^a   Hann, Lucy E ^a   Colon, Jasmine ^a   Spriggs, David ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANXIETY; ARTICLE; BENIGN TUMOR; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COMPARATIVE STUDY; DEPRESSION; DIAGNOSTIC TEST; FAMILY HISTORY; FEMALE; HIGH RISK POPULATION; HUMAN; LABORATORY DIAGNOSIS; LIFESPAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OUTCOMES RESEARCH; OVARY CANCER; OVARY CYST; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SALPINGOOOPHORECTOMY; SCREENING TEST; SOLID TUMOR;

EID: 0038173764     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00147-1     Document Type: Article

References (25)

1. Stratton J.R., Pharoah P., Smith S.K., Easton D., Ponder B.A.J. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol. 105:1998;493-499.
2. Easton D., Matthew F., Ford D., Swerdlow A., Peto J. Cancer mortality in relatives of women with ovarian cancer the OPCS study . Int J Cancer. 65:1996;284-294.
3. Easton D.F., Ford D., Bishop D.T., et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet. 56:1995;265-271.
4. Whittemore A.S., Gong G., Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer results from three US population-based case-control studies of ovarian cancer . Am J Hum Genet. 60:1997;496-504.
5. Kauff N.D., Satagopan J.M., Robson M.E., Scheuer L., Hensley M., Hudis C., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 346:2002;1609-1615.
6. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutation. N Engl J Med. 346:2002;1616-1622.
7. Burke W., Daly M., Garber J., et al. Recommendations for follow-up care of individuals with inherited predisposition to cancer. II. BRCA1 and BRCA2. JAMA. 277:1997;997-1003.
8. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 1996;15:1730-6.
9. Fluctuations in CA125 and CA15-3 serum concentrations during spontaneous ovulatory cycles. Hum Reprod 1999;14:566-70.
10. Nonogaki H., Fujii S., Konishi I., Nanbu Y., Kobayashi F., Mori T. Serial changes of serum CA125 levels during menstrual cycles. Asia Oceania J Obstet Gynaecol. 17:1991;369-378.
11. Imai A., Horibe S., Takagi A., Takagi H., Tamaya T. Drastic elevation of serum CA125, CA 72-4 and CA19-9 levels during menses in a patient with probable endometriosis. Eur J Obstet Gynecol Reprod Biol. 78:1998;79-81.
12. Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 75:2000;264-265.
13. McHorney C.A., Ware J.E., Raczek A.E. The MOS 36-item Short Form Health Survey (SF-36). II. Psychometric and clinical test of validity in measuring physical and mental health constructs. Med Care. 31:1993;247-263.
14. Horowitz M., Wilner N., Alvarez W. Impact of events scale a measure of subjective stress . Psychosom Med. 41:1979;209-218.
15. Radloff L.S. The CES-D scale a self-report depression scale for research in the general population . Appl Psychol Measure. 1:1977;385-401.
16. Weinstein N.D. Unrealistic optimism about susceptibility to health problems. J Behav Med. 5:1982;441-460.
17. Ware JE Jr, Snow KK, Kosinski M, Gandek B, SF-36 Health Survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
18. Testa M.A., Simonson D.C. Assessment of quality of life outcomes. N Engl J Med. 334:1996;835-840.
19. Capelli G., De Vincenzo R.I., Addamo A., Bartolozzi F., Braggio N., Scambia G. Which dimensions of health-related quality of life are altered in patients attending the different gynecologic oncology health care settings? Cancer. 95:2002;2500-2507.
20. Robinson G.E., Rosen B.P., Bradley L.N., et al. Psychological impact of screening for familial ovarian cancer reactions to initial assessment . Gynecol Oncol. 65:1997;197-205.
21. Schwartz M.D., Lerman C., Miller S.M., Daly M., Masny A. Coping disposition, perceived risk, and psychological distress among women at increased risk for ovarian cancer. Health Psychol. 14:1995;232-235.
22. Wertz D.C., Sorenso J.R., Heeren T.C. Client's impression of risk provided in genetic counseling. Am J Hum Genet. 39:1986;253-264.
23. Garber C., Wang S.J., Karlan B., et al. Efficacy of genetic counselling in an ovarian cancer early detection program. Am J Hum Genet. 53:1993;A44.
24. Wardle F.J., Pope R. The psychological costs of screening for cancer. J Pscyhosom Res. 35:1992;609-624.
25. Wardle F.J., Collins W., Pernet A.L., et al. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst. 85:1993;653-657.